Dominant negative MORT1/FADD rescues mice from CD95 and TNF-induced liver failure

Hepatology

Volumn 37, Issue 1, 2003, Pages 129-135

  Schuchmann, Marcus ^a   Varfolomeev, Eugene E ^b   Hermann, Frank ^c   Rueckert, Felix ^a   Strand, Dennis ^a   Koehler, Heinz ^c   Strand, Susanne ^a   Lohse, Ansgar W ^a   Wallach, David ^b   Galle, Peter R ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; FAS ANTIBODY; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREEDING; CAUSE OF DEATH; CELL DEATH; CONTROLLED STUDY; DISEASE SEVERITY; GENE EXPRESSION; HEPATITIS; INFLAMMATION; LIGAND BINDING; LIVER CELL; LIVER DEVELOPMENT; LIVER FAILURE; LIVER HEMORRHAGE; LIVER HISTOLOGY; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SURVIVAL; TRANSGENE; TRANSGENIC MOUSE; WILD TYPE;

EID: 0037222024     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50011     Document Type: Article

References (28)

1. Galle PR. Apoptosis in liver disease. J Hepatol 1997;27:405-412.
2. Caraceni P, Van Thiel DH. Acute liver failure. Lancet 1995;345:163-169.
3. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995;182:1223-1230.
4. Streetz K, Leifeld L, Grundmann D, Ramakers J, Eckert K, Spengler U, Brenner D, et al. Tumor necrosis factor α in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 2000;119:446-460.
5. Schuchmann M, Galle PR. Apoptosis in liver disease. Eur J Gastroenterol Hepatol 2001;13:785-790.
6. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997;3:409-413.
7. Nagata S. Apoptosis by death factor. Cell 1997;88:355-365.
8. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999;17:331-367.
9. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO1- and TNF receptor-induced cell death. Cell 1996;85:803-815.
10. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-827.
11. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 I contains a sequence motif related to the death domain. J Biol Chem 1995;270: 7795-7798.
12. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-512.
13. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 1995;81:495-504.
14. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000;12:599-609.
15. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000;2:241-243.
16. Kuang AA, Diehl GE, Zhang J, Winoto A. FADD is required for DR4-and DR5-mediated apoptosis: Lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J Biol Chem 2000;275:25065-25068.
17. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12:611-620.
18. Newton K, Harris AW, Bath ML, Smith KGC, Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J 1998;17:706-718.
19. Walsh CM, Wen BG, Chinnaiyan AM, O'Rourke K, Dixit VM, Hedrick SM. A role for FADD in T cell activation and development. Immunity 1998;8:439-449.
20. Yeh W, de la Pompa JL, McCurrach ME, Shu H, Elia AJ, Shahinian A, Ng M, et al. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998;279:1954-1958.
21. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/MORT1. Nature 1998;392:296-300.
22. Chaffin KE, Beals CR, Wilkie TM, Forbush KA, Simon MI, Perlmutter RM. Dissection of thymocyte signaling pathways by in vivo expression of pertussis toxin ADP-ribosyltransferase. EMBO J 1990;9:3821-3829.
23. Pinkert CA, Ornitz DM, Brinster RL, Palmiter RD. An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Genes Dev 1987;1:268-276.
24. Lehmann V, Freudenberg MA, Galanos C. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J Exp Med 1987;165:657-663.
25. Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N, Nagata S. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995;11:294-300.
26. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789-795.
27. Latta M, Kunstle G, Leist M, Wendel A. Metabolic depletion of ATP by fructose inversely controls CD95- and tumor necrosis factor receptor 1-mediated hepatic apoptosis. J Exp Med 2000; 191:1975-1985.
28. Seino K, Setoguchi Y, Ogino T, Kayagaki N, Akiba H, Nakano H, Taniguchi H, et al. Protection against Fas-mediated and tumor necrosis factor receptor 1-mediated liver injury by blockade of FADD without loss of nuclear factor-κB activation. Ann Surg 2001;234:681-688.